Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

621 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lung Cancer Proteogenomics: Shaping the Future of Clinical Investigation.
Vavilis T, Petre ML, Vatsellas G, Ainatzoglou A, Stamoula E, Sachinidis A, Lamprinou M, Dardalas I, Vamvakaris IN, Gkiozos I, Syrigos KN, Anagnostopoulos AK. Vavilis T, et al. Among authors: syrigos kn. Cancers (Basel). 2024 Mar 21;16(6):1236. doi: 10.3390/cancers16061236. Cancers (Basel). 2024. PMID: 38539567 Free PMC article. Review.
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.
Charpidou A, Gerotziafas G, Popat S, Araujo A, Scherpereel A, Kopp HG, Bironzo P, Massard G, Jiménez D, Falanga A, Kollias A, Syrigos K. Charpidou A, et al. Among authors: syrigos k. Cancers (Basel). 2024 Jan 20;16(2):450. doi: 10.3390/cancers16020450. Cancers (Basel). 2024. PMID: 38275891 Free PMC article. Review.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Among authors: syrigos k. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M. Saalfeld FC, et al. Among authors: syrigos kn. Eur J Cancer. 2024 Oct 12;213:115065. doi: 10.1016/j.ejca.2024.115065. Online ahead of print. Eur J Cancer. 2024. PMID: 39423775 Free article.
Combined use of radiotherapy and tyrosine kinase inhibitors in the management of metastatic non-small cell lung cancer: A literature review.
Georgakopoulos I, Kouloulias V, Ntoumas G, Desse D, Koukourakis I, Kougioumtzopoulou A, Charpidou A, Syrigos KN, Zygogianni A. Georgakopoulos I, et al. Among authors: syrigos kn. Crit Rev Oncol Hematol. 2024 Sep 19;204:104520. doi: 10.1016/j.critrevonc.2024.104520. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 39304035 Review.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs.
Evangelou G, Vamvakaris I, Konstantopoulou I, Syrigos K. Evangelou G, et al. Among authors: syrigos k. Oncology (Williston Park). 2024 Jul 8;38(7):264-268. doi: 10.46883/2024.25921024. Oncology (Williston Park). 2024. PMID: 39024198 Free article.
621 results